Infections with Candida albicans are still a major problem in immunocompromised and hospitalized patients leading to a large number of death and costs for health care systems worldwide. Extensive genetic and population wide studies have identified important components in Candida host response pathways that are dysregulated that are responsible for disease susceptibility. The intracellular interleukin (IL)-32 has recently been described to be important in several bacterial infections but nothing is known about its role in fungal infections.

The role of IL-32 in the innate host response against Candida albicans